Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KYMR with free AI briefings, catalyst countdowns, and dilution alerts.

KYMR · Kymera Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.6B Cash on Hand
74.8mo Cash Runway
Follow KYMR by email Get an email when KYMR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KYMR, unsubscribe in one click. Privacy

📣 What KYMR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
KT-621 Atopic Dermatitis Phase 2 · NCT07217015 Active not recruiting
SAR444656 (KT-474) Atopic Dermatitis Phase 2 · NCT06058156 Terminated
MDM2 Degrader KT-253 Myeloid Malignancies Phase 1 · NCT05775406 Completed
Lirodegimod (KT-333) Non Hodgkin Lymphoma (NHL) Phase 1 · NCT05225584 Completed
Zomiradomide (KT-413) Non Hodgkin Lymphoma Phase 1 · NCT05233033 Completed
KT-474 Healthy Volunteer Phase 1 · NCT04772885 Completed
KT-579 Healthy Participants Phase 1 · NCT07412288 Completed
SAR447971 Hidradenitis Phase 1 · NCT07629336 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KYMR holds $1.6B in cash and short-term investments (as of Sep 30, 2026) and burns about $66M/quarter from operations, an estimated runway of 74.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 17 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KYMR files for a raise →

👥 Who Owns KYMR

Insiders 2.2% Institutions (421 holders) 97.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 11,681,450 13.68% 2026-03-31
T. Rowe Price Associates, Inc. Institution (13G, 5%+) 8,873,588 10.39% 2026-08-31
Baker Bros. Advisors LP Institution (13G, 5%+) 8,676,797 10.16% 2025-12-09
T. Rowe Price Investment Management, Inc Institution (13G, 5%+) 5,460,257 6.40% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 5,450,286 6.38% 2026-09-30
Nello Mainolfi
Chief Executive Officer, Director · +60,000 options
Insider 666,568 0.78% 2026-10-01
Bruce Booth
Director · +34,195 options
Insider 462,856 0.54% 2026-06-26
BVF PARTNERS L P/IL
Director · +150,055 options
Insider 318,910 0.37% 2026-06-26
Bruce N. Jacobs
Chief Financial Officer
Insider 244,883 0.29% 2026-06-30
Brian Adams
Chief Legal Officer
Insider 50,254 0.06% 2026-09-04
Noah Goodman
Chief Business Officer · +90,000 options
Insider 47,179 0.06% 2026-07-01
Jeremy G Chadwick
Chief Operating Officer · +103,697 options
Insider 44,018 0.05% 2026-05-26

Share count 85,371,397 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KYMR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYMR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.